This book covers pharmacological activity and the role of the medications used for the medical management of obesity. The chapters provide information on the prevalence of obesity, basic principles of obesity management, a brief history of anti-obesity medications (AOMs), and discontinuation of AOMs due to their safety concerns. Further chapters include information on currently approved AOMs for obesity management by healthcare regulatory authorities including their effect on weight loss and other important clinical parameters, short-term and long-term use of AOMs, medications for genetic obesity, and the use of AOMs in obesity with associated co-morbidities as per their safety considerations and contraindications. A separate chapter is on drugs that are either under a clinical trial phase or awaiting approval. The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the external editor. The editor of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that the auto-summaries consist of original sentences, but are not representative of the original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here and that machine-generated books are still at an experimental stage The book is relevant for healthcare and pharmaceutical professionals.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Dr. Shilpa Chugh Garcha (MBBS, MD Pharmacology) completed her graduation in medicine from Dayanand Medical College and Hospital, Ludhiana, India; postgraduation from Government Medical College, Patiala, India. She has worked as an assistant professor of pharmacology at SGT Medical College, Haryana, India. Dr. Shilpa was also part of the medical affairs team of Novo Nordisk India, wherein her primary work was medico-marketing of newer diabetes therapies. She worked at Baxter India as a clinical marketing advisor for IV fluids and parenteral nutrition. Dr. Shilpa also worked as a senior manager, medical affairs, at 1mg.com and was responsible for editing and reviewing drug-related medical information for patients.
Dr. Sanjay Kalra (MBBS, MD, DM) completed his graduation in medicine from Punjab University, Chandigarh, India; post-graduation in medicine from Maharshi Dayanand University, Rohtak, India; doctorate of medicine in endocrinology from All India Institute of Medical Sciences, New Delhi, India. He is working as an endocrinologist at Bharti Hospital, Karnal, India. Dr. Sanjay is currently the Treasurer, International Society of Endocrinology, and Vice President, South Asian Obesity Forum. Dr. Sanjay was president of the South Asian Federation of Endocrine Societies (SAFES); chairperson of the Education Working Group, the International Society of Endocrinology, and president of the Indian Professional Association of Transgender Health. In the past, he was also the president of the Endocrine Society of India. He was part of the editorial board of Diabetes Therapy, European Endocrinology, and the Indian Journal of Endocrinology and Metabolism. Dr. Sanjay works to spread endocrine and diabetes awareness across the world.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Paperback. Etat : new. Paperback. This book covers pharmacological activity and the role of the medications used for the medical management of obesity. The chapters provide information on the prevalence of obesity, basic principles of obesity management, a brief history of anti-obesity medications (AOMs), and discontinuation of AOMs due to their safety concerns. Further chapters include information on currently approved AOMs for obesity management by healthcare regulatory authorities including their effect on weight loss and other important clinical parameters, short-term and long-term use of AOMs, medications for genetic obesity, and the use of AOMs in obesity with associated co-morbidities as per their safety considerations and contraindications. A separate chapter is on drugs that are either under a clinical trial phase or awaiting approval.The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the external editor. The editor of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that the auto-summaries consist of original sentences, but are not representative of the original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here and that machine-generated books are still at an experimental stageThe book is relevant for healthcare and pharmaceutical professionals. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9789819616534
Quantité disponible : 1 disponible(s)
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware Englisch. N° de réf. du vendeur 9789819616534
Quantité disponible : 2 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. N° de réf. du vendeur 3257530609
Quantité disponible : Plus de 20 disponibles
Vendeur : CitiRetail, Stevenage, Royaume-Uni
Paperback. Etat : new. Paperback. This book covers pharmacological activity and the role of the medications used for the medical management of obesity. The chapters provide information on the prevalence of obesity, basic principles of obesity management, a brief history of anti-obesity medications (AOMs), and discontinuation of AOMs due to their safety concerns. Further chapters include information on currently approved AOMs for obesity management by healthcare regulatory authorities including their effect on weight loss and other important clinical parameters, short-term and long-term use of AOMs, medications for genetic obesity, and the use of AOMs in obesity with associated co-morbidities as per their safety considerations and contraindications. A separate chapter is on drugs that are either under a clinical trial phase or awaiting approval.The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the external editor. The editor of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that the auto-summaries consist of original sentences, but are not representative of the original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here and that machine-generated books are still at an experimental stageThe book is relevant for healthcare and pharmaceutical professionals. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. N° de réf. du vendeur 9789819616534
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This book covers pharmacological activity and the role of the medications used for the medical management of obesity. The chapters provide information on the prevalence of obesity, basic principles of obesity management, a brief history of anti-obesity medications (AOMs), and discontinuation of AOMs due to their safety concerns. Further chapters include information on currently approved AOMs for obesity management by healthcare regulatory authorities including their effect on weight loss and other important clinical parameters, short-term and long-term use of AOMs, medications for genetic obesity, and the use of AOMs in obesity with associated co-morbidities as per their safety considerations and contraindications. A separate chapter is on drugs that are either under a clinical trial phase or awaiting approval.The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the external editor. The editor of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that the auto-summaries consist of original sentences, but are not representative of the original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here and that machine-generated books are still at an experimental stageThe book is relevant for healthcare and pharmaceutical professionals. N° de réf. du vendeur 9789819616534
Quantité disponible : 1 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg Englisch. N° de réf. du vendeur 9789819616534
Quantité disponible : 1 disponible(s)
Vendeur : AussieBookSeller, Truganina, VIC, Australie
Paperback. Etat : new. Paperback. This book covers pharmacological activity and the role of the medications used for the medical management of obesity. The chapters provide information on the prevalence of obesity, basic principles of obesity management, a brief history of anti-obesity medications (AOMs), and discontinuation of AOMs due to their safety concerns. Further chapters include information on currently approved AOMs for obesity management by healthcare regulatory authorities including their effect on weight loss and other important clinical parameters, short-term and long-term use of AOMs, medications for genetic obesity, and the use of AOMs in obesity with associated co-morbidities as per their safety considerations and contraindications. A separate chapter is on drugs that are either under a clinical trial phase or awaiting approval.The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the external editor. The editor of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that the auto-summaries consist of original sentences, but are not representative of the original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here and that machine-generated books are still at an experimental stageThe book is relevant for healthcare and pharmaceutical professionals. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. N° de réf. du vendeur 9789819616534
Quantité disponible : 1 disponible(s)